378,205 Shares in HilleVax, Inc. (NASDAQ:HLVX) Bought by Trium Capital LLP

Trium Capital LLP bought a new position in shares of HilleVax, Inc. (NASDAQ:HLVX - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 378,205 shares of the company's stock, valued at approximately $548,000. Trium Capital LLP owned 0.75% of HilleVax at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Millennium Management LLC raised its stake in shares of HilleVax by 59.6% in the 4th quarter. Millennium Management LLC now owns 411,820 shares of the company's stock valued at $852,000 after acquiring an additional 153,815 shares during the period. Two Sigma Advisers LP grew its holdings in shares of HilleVax by 76.8% in the fourth quarter. Two Sigma Advisers LP now owns 41,200 shares of the company's stock valued at $85,000 after purchasing an additional 17,900 shares in the last quarter. Takeda Pharmaceutical Co. Ltd. acquired a new position in shares of HilleVax in the fourth quarter valued at approximately $13,919,000. Bank of Montreal Can grew its holdings in shares of HilleVax by 47.1% in the fourth quarter. Bank of Montreal Can now owns 35,763 shares of the company's stock valued at $74,000 after purchasing an additional 11,459 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new position in shares of HilleVax in the fourth quarter valued at approximately $26,000. 86.42% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "neutral" rating and issued a $2.00 price objective on shares of HilleVax in a report on Monday, March 31st.

HilleVax Stock Down 0.5%

NASDAQ HLVX traded down $0.01 on Friday, hitting $2.09. 104,764 shares of the stock were exchanged, compared to its average volume of 308,710. HilleVax, Inc. has a fifty-two week low of $1.34 and a fifty-two week high of $2.15. The company has a market cap of $104.79 million, a PE ratio of -0.97 and a beta of 0.76. The company has a 50-day moving average price of $1.94 and a 200-day moving average price of $1.85.

HilleVax (NASDAQ:HLVX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.25. As a group, equities research analysts predict that HilleVax, Inc. will post -2.64 EPS for the current fiscal year.

HilleVax Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.